Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This phase II trial tests whether yttrium Y 90 glass microspheres, atezolizumab, and cabozantinib work to shrink tumors in patients with liver cancer (hepatocellular carcinoma) that cannot be removed by surgery (unresectable) or that has spread to nearby tissue or lymph nodes (locally advanced). Yttrium Y 90 glass microspheres consists of millions of microscopic glass spheres containing yttrium-90, a radioactive substance. Yttrium Y 90 glass microspheres are delivered to the tumor in the liver through a catheter in an artery. Radiation from the Yttrium-90 helps treat the tumor. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The combination of yttrium Y 90 glass microspheres, atezolizumab, and cabozantinib may kill more tumor cells.
Full description
PRIMARY OBJECTIVE:
I. To assess proportion of participants that are progression-free at 6 months.
SECONDARY OBJECTIVES:
I. To assess objective response rate (ORR) for study intervention. II. To assess disease control rate (DCR) for study intervention. III. To assess time to disease progression (TTP) for study intervention. IV. To observe progression-free survival. V. To observe overall survival (OS) for study intervention. VI. To assess safety of study intervention.
EXPLORATORY OBJECTIVE:
I. To evaluate therapy induced changes in the tumor and tumor immune microenvironments.
OUTLINE:
CYCLE 1: Patients receive atezolizumab intravenously (IV) over 60 minutes on day 1. Within 14 days, patients receive yttrium Y 90 glass microspheres (Y-90) intra-arterially.
CYCLES 2+: Patients receive atezolizumab IV over 60 minutes on day 1 and cabozantinib S-malate (cabozantinib) orally (PO) once daily (QD) on days 1-21. Treatment repeats every 21 days for a total of 12 cycles in the absence of disease progression or unacceptable toxicity. Patients deriving clinical benefit may continue receiving atezolizumab and cabozantinib beyond cycle 12 at the discretion of the principal investigator (PI).
After completion of study treatment, patients are followed up at 30 days and then every 6 months until 2 years from first dose of study drug.
Sex
Ages
Volunteers
Inclusion criteria
Participant must provide written informed consent before any study-specific procedures or interventions are performed
Participants aged >= 18 years
Capable of understanding and complying with the protocol requirements and must have signed the informed consent document
Patients must have histologically or cytologically confirmed hepatocellular cancer that is not amenable to transplant or resection:
Disease must not be amenable to surgical resection, transplantation, or thermal ablation, or recurrent hepatocellular carcinoma (HCC) after a previous definitive therapy (surgery or thermoablative therapy)
Venous invasion (portal, hepatic, inferior vena cava [IVC], biliary) and infiltrative growth pattern are eligible
Eastern Cooperative Oncology Group (ECOG) 0 - 1
Recovery to baseline or =< grade 1 (per Common Terminology Criteria for Adverse Events [CTCAE] version [v]5.0) from toxicities related to any prior treatments, unless adverse events (AE[s]) are clinically non-significant and/or stable on supportive therapy
Hemoglobin >= 9 g/dL (>= 90 g/L) (within 14 days before first dose of study treatment)
White blood cell count >= 2500/uL (within 14 days before first dose of study treatment)
Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (1500/uL), without granulocyte colony-stimulating factor (GSF) support (within 14 days before first dose of study treatment)
Platelet count >= 60 x 10^9/L (>= 60,000/uL), without transfusion (within 14 days before first dose of study treatment)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 5 x upper limit of normal (ULN) (within 14 days before first dose of study treatment)
Alkaline phosphatase (ALP) =< 5 x ULN (within 14 days before first dose of study treatment)
Total bilirubin =< 2 mg/dL (=< 34.2 umol/L) (within 14 days before first dose of study treatment)
Serum albumin >= 2.8 g/dL (within 14 days before first dose of study treatment)
Prothrombin time/international normalized ratio (PT/INR) or partial thromboplastin time (PTT) test < 1.3 x laboratory ULN (within 14 days before first dose of study treatment)
Serum creatinine =< 1.5 x ULN or calculated creatinine clearance >= 40 mL/min (>= 0.675 mL/sec) using the Cockcroft-Gault equation (within 14 days before first dose of study treatment)
Urine protein/creatinine ratio (UPCR) =< 1 mg/mg (=< 113.2 mg/mmol), or 24-hour (h) urine protein =< 1 g (within 14 days before first dose of study treatment)
Has at least one measurable lesion based on Modified Response Evaluation Criteria in Solid Tumors (mRECIST)
Eligible for Y-90 radioembolization based on planning angiogram and evidence of >= 30% hepatic reserve (untreated background liver)
Participants must have at least one measurable site of disease as defined by mRECIST that is amendable to biopsy
Must agree to undergo 2 mandatory on-study tumor biopsies (at time of Y-90 radioembolization and after completing the initial combination cycle of atezolizumab and cabozantinib). A third on-study biopsy at time of disease progression is optional but not mandatory
Sexually active fertile participants and their partners must agree to use medically accepted methods of contraception (e.g., barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the course of the study and for 4 months after the last dose of cabozantinib and 5 months after the last dose of atezolizumab
Participants of childbearing potential must not be pregnant at screening. Participants are considered to be of childbearing potential unless one of the following criteria is met:
Exclusion criteria
Another primary tumor
Extrahepatic metastases
Advanced liver disease with a Child-Pugh B or C, or active gastrointestinal bleeding or encephalopathy or refractory ascites
Prior systemic therapy for HCC
Prior Y-90 radioembolization. Prior chemoembolization is permitted
Radiation therapy for bone metastasis within 2 weeks or any other radiation therapy within 4 weeks before first dose of study treatment. Systemic treatment with radionuclides within 6 weeks before first dose of study treatment. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible
Prior treatment with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another co-inhibitory T-cell receptor (e.g. CTLA-4, OX-40, and CD137). Note: Patients who have received their first dose of atezolizumab as a first-line treatment of their HCC no longer than 21 days from signing consent, may still be eligible
Prior treatment with cabozantinib
Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment
Participants cannot be on other forms of anti-cancer therapy at the same time, except as described within this protocol
Concomitant anticoagulation with coumarin agents (e.g., warfarin), direct thrombin inhibitors (e.g., dabigatran), direct factor Xa inhibitors (e.g., rivaroxaban), or platelet inhibitors (e.g., clopidogrel). Allowed anticoagulants are the following:
Participant has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:
Cardiovascular disorders:
Congestive heart failure New York Heart Association class 3 or 4, unstable angina pectoris, serious cardiac arrhythmias
Uncontrolled hypertension defined as sustained blood pressure (BP) > 140 mm Hg systolic or > 90 mm Hg diastolic despite optimal antihypertensive treatment
Stroke (including transient ischemic attack [TIA]), myocardial infarction (MI), or other ischemic event, or thromboembolic event (e.g., deep venous thrombosis, pulmonary embolism) within 6 months before first dose of study treatment
Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation:
Clinically significant hematuria, hematemesis, or hemoptysis of > 0.5 teaspoon (2.5 ml) of red blood, or other history of significant bleeding (e.g., pulmonary hemorrhage) within 12 weeks before start of study intervention
Elevated lung shunting precluding safe treatment with Y-90 within acceptable thresholds of lung exposure (< 30 Gy/treatment; < 50 Gy total)
Patients with anticipated < 30% liver reserve after Y-90 treatment
Patients in whom Y-90 is deemed unsafe due to risks of extra-pulmonary non-target embolization
Patients with renal failure currently requiring dialysis of any kind are not eligible
Cavitating pulmonary lesion(s) or known endotracheal or endobronchial disease manifestation
Lesions invading or encasing any major blood vessels. Participants with lesions invading the intrahepatic vasculature, including portal vein, hepatic vein, and hepatic artery, are eligible
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or to any component of the atezolizumab formulation
Other clinically significant disorders that would preclude safe study participation
Any active, known or suspected autoimmune disease will be excluded, with the following exceptions:
Any condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days before first dose of study treatment
Active infection requiring systemic treatment including acquired immunodeficiency syndrome (AIDS)-related illness, or known positive test for tuberculosis infection where there is clinical or radiographic evidence of active mycobacterial infection. Exceptions to this are as follows:
History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
Serious non-healing wound/ulcer/bone fracture
Malabsorption syndrome
Uncompensated/symptomatic hypothyroidism
Requirement for hemodialysis or peritoneal dialysis
History of solid organ or allogenic stem cell transplant
Prior allogeneic stem cell or solid organ transplantation
Receipt of a live, attenuated vaccine within 4 weeks prior to enrollment or anticipation that a live, attenuated vaccine will be required during atezolizumab treatment or within 5 months after the last dose of atezolizumab
Treatment with systemic immunostimulatory agents (including but not limited to interferons or interleukin [IL]-2) within 4 weeks or five half-lives of the drug (whichever is longer) prior to start of study intervention
Poor peripheral venous access
Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol, safety of participation, or interpretation of results. This includes significant liver disease (such as cirrhosis, uncontrolled major seizure disorder, or superior vena cava syndrome) or any other serious medical condition or abnormality in clinical laboratory tests that meet these criteria in the investigator's opinion
Major surgery (e.g., laparoscopic nephrectomy, GI surgery, removal or biopsy of brain metastasis) within 2 weeks before first dose of study treatment. Minor surgeries within 10 days before first dose of study treatment. Participants must have complete wound healing from major surgery or minor surgery before first dose of study treatment. Participant with clinically relevant ongoing complications from prior surgery are not eligible
Corrected QT interval calculated by the Fridericia formula (QTcF) > 500 ms per electrocardiogram (ECG) within 14 days before first dose of study treatment. Furthermore, participants with a history of additional risk factors for torsades de pointes (e.g., long QT syndrome) are also excluded
Patient is pregnant or lactating
Inability to swallow tablets or unwillingness or inability to receive IV administration
Previously identified allergy or hypersensitivity to the study agents or their excipients or components, or history of severe infusion-related reactions to monocl
Primary purpose
Allocation
Interventional model
Masking
0 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal